Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
Purpose: The aim of this study was to present the outcomes of the 2018 and 2020 Vitreo-retinal Society of India (VRSI) biosimilars of anti-vascular endothelial growth factor (VEGF) (VIBE) surveys. Methods: An online survey of members of VRSI was conducted in July 2018 and January 2020 regarding thei...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Indian Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=2;spage=352;epage=356;aulast=Sheth |
id |
doaj-0a3f1c9fff19430a9f61a1db19d38bcd |
---|---|
record_format |
Article |
spelling |
doaj-0a3f1c9fff19430a9f61a1db19d38bcd2021-02-03T06:18:04ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892021-01-0169235235610.4103/ijo.IJO_2703_20Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF SurveyJay U ShethMichael W StewartManoj KhatriShashank R GuptaShobhit ChawlaAnand RajendranRaja NarayananPurpose: The aim of this study was to present the outcomes of the 2018 and 2020 Vitreo-retinal Society of India (VRSI) biosimilars of anti-vascular endothelial growth factor (VEGF) (VIBE) surveys. Methods: An online survey of members of VRSI was conducted in July 2018 and January 2020 regarding their practice-patterns on anti-VEGF biosimilars pertaining to safety, efficacy, pricing, and need for enhanced clinical trials before regulatory approval. Results: In 2018, 112 VRSI members participated, whereas in 2020, 98 society members participated. In both surveys, majority of respondents were aware of biosimilars (96%, 2018 vs. 100%, 2020; P = 0.9) and felt that approval of biosimilar drugs should be made more stringent with larger clinical trials (89%, 2018 vs. 91%, 2020; P = 0.93). An increase in use of ranibizumab-biosimilar (41%, 2018 to 56%, 2020; P = 0.2) and a simultaneous significant decline in use of bevacizumab-biosimilar (9%, 2018 to 2%, 2020; P = 0.04) was noted from 2018 to 2020. From 2018 to 2020, the proportion of respondents satisfied with safety (61% to 68%; P = 0.59) and efficacy (65% to 81%; P = 0.32) of ranibizumab-biosimilar increased. However, during the same period, we noted in reduction in satisfaction levels with safety of bevacizumab-biosimilar (30% to 25%; P = 0.54), whereas satisfaction with its efficacy was stable (29% vs 30%; P = 0.99). A substantial proportion of retina specialists considered that current cost of ranibizumab-biosimilar ($130) was sufficiently low for it to be used as a substitute for Avastin (37%, 2018 and 40%, 2020; P = 0.82). Conclusion: The VRSI surveys reveal that Indian vitreoretinal specialists are familiar with anti-VEGF biosimilars. There was a progressive trend favoring ranibizumab-biosimilar over bevacizumab-biosimilar. One-third of the participants deem the current price of ranibizumab-biosimilar as appropriate to replace Avastin. Simultaneously, the need for enhanced pharmacovigilance and larger clinical trials are warranted for regulatory approval of these agents.http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=2;spage=352;epage=356;aulast=Shethbevacizumabbiosimilarsranibizumabrazumabvitreoretinal society of india |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jay U Sheth Michael W Stewart Manoj Khatri Shashank R Gupta Shobhit Chawla Anand Rajendran Raja Narayanan |
spellingShingle |
Jay U Sheth Michael W Stewart Manoj Khatri Shashank R Gupta Shobhit Chawla Anand Rajendran Raja Narayanan Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey Indian Journal of Ophthalmology bevacizumab biosimilars ranibizumab razumab vitreoretinal society of india |
author_facet |
Jay U Sheth Michael W Stewart Manoj Khatri Shashank R Gupta Shobhit Chawla Anand Rajendran Raja Narayanan |
author_sort |
Jay U Sheth |
title |
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey |
title_short |
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey |
title_full |
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey |
title_fullStr |
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey |
title_full_unstemmed |
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey |
title_sort |
changing trends in the use of anti-vascular endothelial growth factor (anti-vegf) biosimilars: insights from the vitreoretinal society of india biosimilars of anti-vegf survey |
publisher |
Wolters Kluwer Medknow Publications |
series |
Indian Journal of Ophthalmology |
issn |
0301-4738 1998-3689 |
publishDate |
2021-01-01 |
description |
Purpose: The aim of this study was to present the outcomes of the 2018 and 2020 Vitreo-retinal Society of India (VRSI) biosimilars of anti-vascular endothelial growth factor (VEGF) (VIBE) surveys. Methods: An online survey of members of VRSI was conducted in July 2018 and January 2020 regarding their practice-patterns on anti-VEGF biosimilars pertaining to safety, efficacy, pricing, and need for enhanced clinical trials before regulatory approval. Results: In 2018, 112 VRSI members participated, whereas in 2020, 98 society members participated. In both surveys, majority of respondents were aware of biosimilars (96%, 2018 vs. 100%, 2020; P = 0.9) and felt that approval of biosimilar drugs should be made more stringent with larger clinical trials (89%, 2018 vs. 91%, 2020; P = 0.93). An increase in use of ranibizumab-biosimilar (41%, 2018 to 56%, 2020; P = 0.2) and a simultaneous significant decline in use of bevacizumab-biosimilar (9%, 2018 to 2%, 2020; P = 0.04) was noted from 2018 to 2020. From 2018 to 2020, the proportion of respondents satisfied with safety (61% to 68%; P = 0.59) and efficacy (65% to 81%; P = 0.32) of ranibizumab-biosimilar increased. However, during the same period, we noted in reduction in satisfaction levels with safety of bevacizumab-biosimilar (30% to 25%; P = 0.54), whereas satisfaction with its efficacy was stable (29% vs 30%; P = 0.99). A substantial proportion of retina specialists considered that current cost of ranibizumab-biosimilar ($130) was sufficiently low for it to be used as a substitute for Avastin (37%, 2018 and 40%, 2020; P = 0.82). Conclusion: The VRSI surveys reveal that Indian vitreoretinal specialists are familiar with anti-VEGF biosimilars. There was a progressive trend favoring ranibizumab-biosimilar over bevacizumab-biosimilar. One-third of the participants deem the current price of ranibizumab-biosimilar as appropriate to replace Avastin. Simultaneously, the need for enhanced pharmacovigilance and larger clinical trials are warranted for regulatory approval of these agents. |
topic |
bevacizumab biosimilars ranibizumab razumab vitreoretinal society of india |
url |
http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=2;spage=352;epage=356;aulast=Sheth |
work_keys_str_mv |
AT jayusheth changingtrendsintheuseofantivascularendothelialgrowthfactorantivegfbiosimilarsinsightsfromthevitreoretinalsocietyofindiabiosimilarsofantivegfsurvey AT michaelwstewart changingtrendsintheuseofantivascularendothelialgrowthfactorantivegfbiosimilarsinsightsfromthevitreoretinalsocietyofindiabiosimilarsofantivegfsurvey AT manojkhatri changingtrendsintheuseofantivascularendothelialgrowthfactorantivegfbiosimilarsinsightsfromthevitreoretinalsocietyofindiabiosimilarsofantivegfsurvey AT shashankrgupta changingtrendsintheuseofantivascularendothelialgrowthfactorantivegfbiosimilarsinsightsfromthevitreoretinalsocietyofindiabiosimilarsofantivegfsurvey AT shobhitchawla changingtrendsintheuseofantivascularendothelialgrowthfactorantivegfbiosimilarsinsightsfromthevitreoretinalsocietyofindiabiosimilarsofantivegfsurvey AT anandrajendran changingtrendsintheuseofantivascularendothelialgrowthfactorantivegfbiosimilarsinsightsfromthevitreoretinalsocietyofindiabiosimilarsofantivegfsurvey AT rajanarayanan changingtrendsintheuseofantivascularendothelialgrowthfactorantivegfbiosimilarsinsightsfromthevitreoretinalsocietyofindiabiosimilarsofantivegfsurvey |
_version_ |
1724288949945368576 |